Effects of continuous positive airway pressure on resolvin and matrix metalloproteinase-9 in patients with obstructive sleep apnea.
Respir Physiol Neurobiol
; 285: 103603, 2021 03.
Article
in En
| MEDLINE
| ID: mdl-33348057
ABSTRACT
PURPOSE:
Resolvin is a checkpoint controller in inflammation. Matrix metalloproteinase-9 (MMP-9) is an airway remodeling regulator. We evaluated the levels of resolvin and MMP-9 protein in the serum and exhaled breath condensate (EBC) before and after continuous positive airway pressure (CPAP) treatment.METHOD:
We enrolled 20 non-OSA snorers and 40 patients with moderate to severe OSA scheduled for CPAP treatment. ELISA was used to assess resolvin and MMP-9 levels in the serum and EBC. All patients underwent sleep assessment at baseline and 3 months after CPAP.RESULTS:
There was no between-group difference; moreover, there were no differences in the pre- and post-treatment serum levels of resolvin and MMP-9 in patients with OSA. Compared with non-OSA snorers, patients with OSA had lower resolvin and higher MMP-9 levels in the EBC. After CPAP treatment, the EBC levels of resolvin and MMP-9 in patients with OSA returned to normal.CONCLUSIONS:
Successful OSA treatment by CPAP can normalize EBC levels of resolvin and MMP-9.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Snoring
/
Docosahexaenoic Acids
/
Inflammation Mediators
/
Sleep Apnea, Obstructive
/
Matrix Metalloproteinase 9
/
Continuous Positive Airway Pressure
Limits:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Respir Physiol Neurobiol
Year:
2021
Document type:
Article